Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis

Figures & data

Figure 1 Flow diagram of study selection.

Figure 2 Kaplan–Meier overall survival curve.

Figure 3 Kaplan–Meier progression-free survival curve.

Table S1 Characteristics of all patients included in the meta-analysis

Reference	Age (pregnancy), years	Gestational age (diagnosis), weeks	Pathological type	FIGO stage	NACT	Gestational age (chemotherapy), weeks	Adverse events during pregnancy	Response evaluation after NACT	Gestational age (delivery), weeks	Method of delivery	Lymph-node status	Treatment time after delivery (first line)	Treatment after delivery (first line)	Further treatment after delivery (second line)	Relapse	Outcome, mother	OS (months)	PFS (months)	Delivery weight (g)	Fetal outcome
^Citation1	35	27	Squamous-cell carcinoma	IB2	2× cisplatin 75 mg/m^2 + paclitaxel 135 mg/m^2, q21d	27	No	MRI: reduction in tumor size (partial response)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH + PLND	RT + CT	No	NED	>39.25	>39.25	2,450	Healthy at birth; acute myeloid leukemia at 22 months; healthy at 37 months
^Citation2	33	16	Small-cell carcinoma	IB2	3× cisplatin 50 mg/m^2 + paclitaxel 135 mg/m^2, q21d	17	No	MRI: tumor mass disappeared (complete response)	31	Cesarean	Negative	31 weeks at cesarean delivery	RH + PLND	RT + CT	No	NED	>38	>38	1,446	Respiratory distress syndrome and erythema at birth; healthy at 2 months
^Citation3	38	NA	Squamous-cell carcinoma	IIA	4× cisplatin 70 mg/m^2, q21d	15	No	MRI: reduction in tumor size (partial response)	34	Cesarean	Negative	1 month after delivery	RH	RT + CT	Yes	DOD	31	NA	1,950	Healthy at 63 months
^Citation3	42	NA	Squamous-cell carcinoma	IIA	5× cisplatin 75 mg/m^2 + paclitaxel 135 mg/m^2, q21d	13	No	MRI: reduction in tumor size (partial response)	31	Cesarean	Negative	31 weeks at cesarean delivery	RH	RT	No	NED	>36	>36	1,520	Healthy at 31 months
^Citation3	34	NA	Squamous-cell carcinoma	IB2	4× cisplatin 75 mg/m^2 + paclitaxel 135 mg/m^2, q21d	18	No	MRI: a reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	None	No	NED	>31	>31	2,485	Healthy at 27 months
^Citation3	35	NA	Squamous-cell carcinoma	IB2	2× cisplatin 75 mg/m^2 + paclitaxel 135 mg/m^2, q21d	28	No	MRI: reduction in tumor size (partial response)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	RT + CT	No	NED	>19	>19	2,450	Healthy at 18 months
^Citation4	33	26	Squamous-cell carcinoma	IIB	2× cisplatin 75 mg/m^2 + paclitaxel 175 mg/m^2, q14d	28	No	MRI: reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	PLND + PALND	RH 6 month after cesarean delivery	No	NED	>80	>80	2,040	Retroperitoneal embryonal rhabdomyosarcoma at 5 years old
^Citation5	NA	15	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	20	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	22	NA	NA	2× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	15	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	19	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	20	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Positive	32 weeks at cesarean delivery	SH	NA	Yes	DOD	NA	NA	NA	NA
^Citation5	NA	19	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	14	NA	NA	4× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	31	Cesarean	Negative	31 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	18	NA	NA	4× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	17	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	TMMR	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	13	NA	NA	4× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	34	Cesarean	Negative	None	None	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	16	NA	NA	4× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	23	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	34	Cesarean	Negative	34 weeks at cesarean delivery	PLND	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	17	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	21	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	19	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	30	Cesarean	Negative	30 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	14	NA	NA	4× carboplatin (area under the curve 5), q21d	NA	NA	NA (stable disease)	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	21	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	20	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	13	NA	NA	4× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	None	None	NA	No	NED	NA	NA	NA	NA
^Citation5	NA	15	NA	NA	3× cisplatin 20 mg/m^2, q21d	NA	NA	NA (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	NA	No	NED	NA	NA	NA	NA
^Citation6	31	19	Adenocarcinoma	IB1	3× cisplatin 60 mg/m^2 + paclitaxel 135 mg/m^2, q21d	22	NA	MRI: reduction in tumor size (partial response)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	None	No	NED	>104	>104	NA	Healthy at 104 months
^Citation6	26	25	Squamous-cell carcinoma	IB1	1× cisplatin 60 mg/m^2 + paclitaxel 135 mg/m^2	30	NA	MRI: reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	CT	No	NED	>24	>24	NA	Healthy at 24 months
^Citation6	38	13	Squamous-cell carcinoma	IB2	4× cisplatin 60 mg/m^2 + paclitaxel 135 mg/m^2, q21d	18	NA	MRI: reduction in tumor size (partial response)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	CT	No	NED	>35	>35	NA	Healthy at 35 months
^Citation7	34	24	Squamous-cell carcinoma	NA	5× cisplatin 70 mg/m^2 + paclitaxel 90 mg/m^2, q7d	26	Thrombocytopenia, neutropenia, and decrease of creatinine clearance	MRI: reduction in tumor size (partial response)	34	Cesarean	NA	After delivery	RT	NA	NA	NA	NA	NA	2,085	Severe perceptive hearing loss at birth
^Citation8	27	19	Adenosquamous carcinoma	IB2	6× cisplatin 75 mg/m^2 + doxorubicin 35 mg/m^2, q14d	20	None	MRI: tumor mass disappeared (complete response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	NA	No	NED	>20	>20	2,100	Healthy at 20 months
^Citation9	37	26	Squamous-cell carcinoma	IB2	4× cisplatin 80 mg/m^2 + paclitaxel 60 mg/m^2, q10d	NA	Nausea + vomiting	Vaginal examination: tumor regression (partial response)	32	Cesarean	Negative	2 weeks after delivery	RH	RT	No	NED	>7.5	>7.5	2,800	Healthy at 6 months
^Citation10	NA	11	Squamous-cell carcinoma	IB2	6× cisplatin 50 mg/m^2, q14d	14	Antepartum hemorrhage and placenta previa	MRI: significant increase in tumor size (disease progression)	28	Cesarean	NA	After delivery	RT + CT	RT + CT	Yes	DOD	24	18	1,800	Healthy at 60 months
^Citation11	24	23	Adenocarcinoma	IB1	2× cisplatin 50 mg/m^2 + vincristine 1 mg/m^2, q28d	26	NA	MRI: reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	CT	No	NED	>24	>24	2,150	Healthy at 6 months
^Citation12	26	18	Clear-cell adenocarcinoma	IB1	3× cisplatin 75 mg/m^2, q21d	19	NA	MRI: tumor mass disappeared (complete response)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	No	NED	>36	>36	1,650; 1,480; 1,580	Healthy at 36 months
^Citation13	29	13	Squamous-cell carcinoma	IB2	Cisplatin 50 mg/m^2 + vincristine 1 mg/m^2, q14d	NA	None	MRI: no change in tumor size (stable disease)	30	Cesarean	Positive	30 weeks at cesarean delivery	RH	RT	Yes	DOD	27	12.25	1,330	Healthy at 22.75 months
^Citation13	37	18	Squamous-cell carcinoma	IB2	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: no change in tumor size (stable disease)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>153	>153	2,890	Healthy at 149.5 months
^Citation13	28	16	Squamous-cell carcinoma	IB2	Cisplatin 75 mg/m^2 + paclitaxel 175 mg/m^2, q21d	NA	Oligohydramnios	MRI: reduction in tumor size (partial response)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	None	Yes	NED	>113	11.25	2,030	Respiratory disorder at birth, received mechanical ventilation; healthy at 108.75 months
^Citation13	36	16	Squamous-cell carcinoma	IB2	Cisplatin 75 mg/m^2 + paclitaxel 175 mg/m^2, q21d	NA	None	MRI: a reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	None	Yes	NED	>115	21.5	1,900	First-degree intraventricular hemorrhage at birth; healthy at 110.5 months
^Citation13	32	20	Squamous-cell carcinoma	IB2	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: no change in tumor size (stable disease)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	RT + CT	Yes	DOD	27	16.75	2,450	Healthy at 23.25 months
^Citation13	34	22	Squamous-cell carcinoma	IB1	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: reduction in tumor size (partial response)	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	None	No	NED	>65	>65	2,990	Healthy at 61.5 months
^Citation13	39	20	Adenocarcinoma	IB1	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: reduction in tumor size (partial response)	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	None	No	NED	>41	>41	2,890	Healthy at 37 months
^Citation13	34	26	Adenocarcinoma	IB1	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: reduction in tumor size (partial response)	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	None	No	NED	>43	>43	2,800	Healthy at 40.5 months
^Citation13	37	8	Squamous-cell carcinoma	IB1	Cisplatin 75 mg/m^2, q21d	NA	None	MRI: no change in tumor size (stable disease)	36	Cesarean	Positive	36 weeks at cesarean delivery	RH	RT + CT	No	NED	>23	>23	2,200	Healthy at 16 months
^Citation14	37	10	Adenocarcinoma	IB2	1× cisplatin (NA)	NA	Intolerance	MRI: reduction in tumor size (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH + PLND	RT + CT	No	NED	>36	>36	2,800	Healthy at 36 months
^Citation15	NA	20	Squamous-cell carcinoma	IB	3× cisplatin (NA), q28d	22	NA	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	RT + CT	No	NED	>19	>19	NA	Healthy at birth
^Citation16	41	14	Squamous-cell carcinoma	IB2	4× cisplatin 20 mg/m^2, q21d	NA	None	NA	31	Cesarean	Negative	31 weeks at cesarean delivery	RH	CT	No	NED	>5.25	>5.25	1,580	Respiratory distress syndrome and hypotension at birth; healthy at 1 months
^Citation17	36	27	Squamous-cell carcinoma	IB2	2× cisplatin 50 mg/m^2 + paclitaxel 75 mg/m^2, q14d	27	None	Vaginal examination: reduction in tumor size (partial response)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	RT + CT	No	NED	>22.5	>22.5	2,200	Healthy at 21 months
^Citation17	39	29	Squamous-cell carcinoma	IB2	2× cisplatin 50 mg/m^2 + paclitaxel 75 mg/m^2, q14d	29	None	Vaginal examination: tumor mass disappeared (complete response)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	None	No	NED	>41	>41	2,200	Healthy at 13 months
^Citation18	30	24	Squamous-cell carcinoma	IIB	4× cisplatin 75 mg/m^2 + vincristine 1 mg/m^2, q21d	25	None	Vaginal examination: tumor mass disappeared (complete response)	37	Vaginal	Negative	3 days after delivery	RH	NA	No	NED	>15.25	>15.25	2,450	Healthy at 12 months
^Citation19	28	20	Squamous-cell carcinoma	IB2	Cisplatin (NA)	21	Miscarriage	NA	22	NA	Negative	After chemotherapy	RH	RT + CT	No	NED	>24	>24	NA	Miscarriage
^Citation19	34	20	Squamous-cell carcinoma	IIA	Cisplatin + vincristine (NA)	23	NA	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>156	>156	1,690	Anemia at birth; healthy
^Citation19	42	24	Squamous-cell carcinoma	IB2	Cisplatin (NA)	27	NA	NA	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	None	No	NED	>36	>36	2,590	Healthy at birth
^Citation20	NA	NA	NA	IB1	Cisplatin + vincristine (NA)	NA	None	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation20	NA	NA	NA	IB1	Cisplatin (NA)	NA	None	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation21	31	18	Squamous-cell carcinoma	IB1	Cisplatin (NA)	NA	None	NA	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	NA	Yes	NED	>104	>10	NA	Healthy at birth
^Citation21	34	22	Squamous-cell carcinoma	IB1	Cisplatin (NA)	NA	None	NA	36	Cesarean	Negative	36 weeks at cesarean delivery	RH	NA	Yes	NED	>51.2	>5	NA	Healthy at birth
^Citation21	31	14	Squamous-cell carcinoma	IB1	Cisplatin (NA)	NA	None	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation21	29	18	Adenocarcinoma	IB1	Cisplatin (NA)	NA	None	NA	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation22	27	25	Small-cell carcinoma	IB1	3× cisplatin 75 mg/m^2 + paclitaxel 175 mg/m^2, q21d	26	NA	MRI: reduction in tumor size (partial response)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	None	Yes	DOD	51.5	48.5	2,570	Healthy at 49 months
^Citation22	32	28	Squamous-cell carcinoma	IIA	1× carboplatin (area under the curve 5) 75 mg/m^2 + paclitaxel 175 mg/m^2	29	NA	Vaginal examination: reduction in tumor size (partial response)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	Refused	No	NED	>33	>33	2,190	Healthy at 48 months
^Citation22	27	28	Squamous-cell carcinoma	IB2	2× cisplatin 75 mg/m^2 + paclitaxel 175 mg/m^2, q21d	33	NA	MRI: reduction in tumor size (partial response)	36	Cesarean	Positive	36 weeks at cesarean delivery	RH	CT	No	NED	>62.25	>62.25	2,600	Healthy at 60 months
^Citation23	27	15	Squamous-cell carcinoma	IB2	4× cisplatin 75 mg/m^2, q21d	18	Anemia grade 3	MRI: mild increase in tumor size (stable disease)	32	Cesarean	Positive	32 weeks at cesarean delivery	RH	RT + CT	Yes	DOD	28.25	16.25	1,920	Respiratory distress syndrome and anemia at birth; healthy at 24 months
^Citation24	26	21	Clear-cell carcinoma	IIB	3× cisplatin 100 mg/m^2, q21d	25	Nausea grade 1, fatigue grade 2	MRI: reduction in tumor size (partial response)	35	Cesarean	NA	After delivery	RT + CT	None	No	NED	>18.75	>18.75	2,380	Hypoglycemia and respiratory disorder at birth; healthy at 15 months
^Citation25	25	NA	NA	NA	Cisplatin (NA)	NA	NA	NA	27	Cesarean	NA	NA	NA	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation25	33	NA	NA	NA	Cisplatin +5-fluorouracil (NA)	NA	NA	NA	34	Cesarean	NA	NA	NA	NA	NA	NA	NA	NA	NA	Healthy at birth
^Citation26	30	23	Glossy-cell carcinoma	IIIB	25 weeks, 27 weeks, 29 weeks: cisplatin 30 mg/m^2 + vincristine 1.5 mg/m^2; 26 weeks, 28 weeks, 30 weeks: cisplatin 40 mg/m^2	25	None	Vaginal examination: decrease in cervical lesions (partial response)	31	Cesarean	Positive	31 weeks at cesarean delivery	PLND +	RT + CT	No	NED	>51.2	>51.2	1,660	Healthy at 49.2 months
16, 21, 27–29	35	15	Adenocarcinoma	IB1	3× cisplatin 20 mg/m^2, q21d	20	Mild nausea and fatigue	MRI: reduction in tumor size (partial response)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>21.5	>21.5	1,790 and 2,020	First neonate healthy at 17 months; second neonate respiratory
16, 27,	31	20	Squamous-cell carcinoma	IB1	3× cisplatin 20 mg/m^2, q21d	NA	None	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>15	>15	1,600	Respiratory distress syndrome at birth; healthy at 12 months
16, 27,	35	22	Squamous-cell carcinoma	IB1	2× cisplatin 20 mg/m^2, q21d	NA	None	NA	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	None	No	NED	>10.25	>10.25	2,600	Respiratory distress syndrome at birth; healthy at 7 months
16, 27,	36	15	Squamous-cell carcinoma	IB1	3× cisplatin 20 mg/m^2, q21d	NA	None	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>7.25	>7.25	1,930	Respiratory distress syndrome at birth; healthy at 3 months
16, 27,	29	19	Adenocarcinoma	IB1	3× cisplatin 20 mg/m^2, q21d	NA	None	NA	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	None	No	NED	>6.5	>6.5	2,290	Respiratory distress syndrome and supraventricular tachycardia at birth; healthy at 3 months
16, 27,	36	20	Squamous-cell carcinoma	IV	3× cisplatin 20 mg/m^2, q21d	NA	None	NA	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	RT + CT	No	NED	>6	>6	1,850	Respiratory distress syndrome at birth; healthy at 3 months
16, 27,	35	19	Adenocarcinoma	IA1	3× cisplatin 20 mg/m^2, q21d	NA	None	NA	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	None	No	NED	>4.75	>4.75	2,960	Respiratory distress syndrome at birth; healthy at 1 months
^Citation30	31	22	Squamous-cell carcinoma	IIIB	2× cisplatin 50 mg/m^2, q14d	24	Preeclamptic syndrome	MRI: significant growth of tumors (disease progression)	28	Cesarean	NA	After delivery	RT + CT	None	Yes	DOD	11.5	0	NA	Healthy at delivery
^Citation31	38	19	Squamous-cell carcinoma	IIA	4× cisplatin 50 mg/m^2 + vincristine 1 mg/m^2, q21d	23	Grade 1 anemia, grade 1 emesis	Vaginal examination: decrease in tumor mass (partial response)	32	Cesarean	Positive	32 weeks at cesarean delivery	RH	CT	No	NED	>80	>80	1,920	Respiratory distress syndrome during the first 32 hours; healthy at 76.75 months
^Citation32	28	23	Squamous-cell carcinoma	IB2	7× cisplatin 40 mg/m^2, q7d	24	None	Vaginal examination: (stable disease)	33	Cesarean	Negative	33 weeks at cesarean delivery	RH	RT + CT	No	NED	>16.5	>16.5	2,450	Mild elevation in serum creatinine at birth; healthy at 14 months
^Citation33	30	20	Squamous-cell carcinoma	IIB	3× cisplatin 75 mg/m^2, q21d	NA	Allergic reaction grade 3 (as a result of paclitaxel)	MRI: reduction in tumor size (partial response)	35	Cesarean	Negative	35 weeks at cesarean delivery	RH	None	No	NED	>13.75	>13.75	2,400	Healthy at 10 months
^Citation34	28	15	Squamous-cell carcinoma	IB1	6× cisplatin 75 mg/m^2, q10d	17	Thrombocytopenia grade 3	MRI: reduction in tumor size (partial response)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>14.25	>14.25	1,715	Healthy at 6 months
^Citation35	26	14	Squamous-cell carcinoma	IIB	2× cisplatin 50 mg/m^2 + bleomycin 30 mg/m^2, q28d	17	None	MRI: reduction in tumor size (partial response)	38	Cesarean	NA	Refused	Refused	None	Yes	DOD	19	18	2,850	Healthy at 36 months
^Citation36	34	16	Squamous-cell carcinoma	IIA	Cisplatin + vincristine (NA)	NA	None	NA (partial response)	34	Cesarean	Negative	34 weeks at cesarean delivery	RH	RT	Yes	NED	>9.5	9.5	2,160	Healthy at birth
^Citation36	36	21	Squamous-cell carcinoma	IB2	Cisplatin + vincristine (NA)	NA	None	NA (partial response)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>26.75	>26.75	1,700	Healthy at 24 months
^Citation37	NA	NA	NA	IB2	3× cisplatin 50 mg/m^2 + vincristine 1 mg/m^2 + bleomycin 25 mg/m^2	NA	NA	Vaginal examination: no change in tumor size (stable disease)	NA	NA	Positive	NA	NA	RT	Yes	DOD	52	35	NA	NA
^Citation37	NA	12	NA	IB2	3× cisplatin 50 mg/m^2 + vincristine 1 mg/m^2 + bleomycin 25 mg/m^2	NA	NA	Vaginal examination: decrease in tumor mass (partial response)	NA	NA	Negative	NA	NA	None	Yes	DOD	59	46	NA	NA
^Citation38	34	17	Squamous-cell carcinoma	I B	3× cisplatin 75 mg/m^2, q21d	22	None	NA (complete response)	32	Cesarean	Negative	32 weeks at cesarean delivery	RH	None	No	NED	>15.75	>15.75	2,120	Healthy at 12 months
^Citation39	25	10	Oat-cell carcinoma	IB	1× cisplatin 50 mg/kg	10	NA	NA (stable disease)	NA	NA	Negative	2 weeks following chemotherapy	RH	RT	No	NED	>9.5	>9.5	None	None

Abbreviations: CT, chemotherapy; DOD, death of disease; FIGO, International Federation of Gynecology and Obstetrics; NACT, neoadjuvant chemotherapy; NA, not available; NED, no evidence of disease; PALND, pelvic-aortic lymphadenectomy; OS, overall survival; PFS, progression-free survival; PLND, pelvic lymphadenectomy; RH, radical hysterectomy; RT, radiotherapy; SH, simple hysterectomy; TMMR, total mesometrial resection.

De VincenzoRTortorellaLRicciCLocally advanced cervical cancer complicating pregnancy: a case of competing risks from the Catholic University of the Sacred Heart in RomeGynecol Oncol2018150339840530126588

 PubMed Web of Science ®Google Scholar

KayahashiKMizumotoYMyojoSMitaniYTajimaAFujiwaraHA successful case of neoadjuvant chemotherapy and radical hysterectomy during pregnancy for advanced uterine cervical cancer accompanied by neonatal erythrodermaJ Obstet Gynaecol Res201844102003200730043438

 PubMed Web of Science ®Google Scholar

RicciCScambiaGde VincenzoRLocally advanced cervical cancer in pregnancy: overcoming the challenge. A case series and review of the literatureInt J Gynecol Cancer20162681490149627575627

 PubMed Web of Science ®Google Scholar

SurboneAAchtariCEmbryonal rhabdomyosarcoma in a child exposed to chemotherapy in utero: a mere coincidence?Eur J Obstet Gynecol Reprod Biol201620723527802874

 PubMed Web of Science ®Google Scholar

KöhlerCOppeltPFaveroGHow much platinum passes the placental barrier? Analysis of platinum applications in 21 patients with cervical cancer during pregnancyAm J Obstet Gynecol20152132206.e1525731691

 PubMed Web of Science ®Google Scholar

KongTWLeeEJLeeYChangSJSonJHRyuHSNeoadjuvant and postoperative chemotherapy with paclitaxel plus cisplatin for the treatment of FIGO stage IB cervical cancer in pregnancyObstet Gynecol Sci201457653954325469346

 PubMedGoogle Scholar

GeijtemanECWensveenCWDuvekotJJvan ZuylenLA child with severe hearing loss associated with maternal cisplatin treatment during pregnancyObstet Gynecol20141242 Pt 2 Suppl 145445625004323

 PubMed Web of Science ®Google Scholar

PeculisLDIusYCampionMFriedlanderMHackerNStage IB2 adenosquamous cervical cancer diagnosed at 19-weeks’ gestationAust N Z J Obstet Gynaecol2015551949725470742

 PubMed Web of Science ®Google Scholar

YousefiZHoshyarAHKadkhodayanSHasanzadeMKalantariMRMottaghiMNeoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer during pregnancy: case report and review of literatureOman Med J2013281606223386949

 PubMedGoogle Scholar

DawoodRInstoneMKehoeSNeo-adjuvant chemotherapy for cervical cancer in pregnancy: a case report and literature reviewEur J Obstet Gynecol Reprod Biol2013171220520824139541

 PubMed Web of Science ®Google Scholar

de LimaCABarcelosACPaschoiniMCConservative treatment of uterine cervical adenocarcinoma in pregnancyCase Rep Obstet Gynecol2013201369201724455354

 PubMedGoogle Scholar

AyhanADursunPKarakayaBKOzenOTarhanCNeoadjuvant chemotherapy followed by cesarean radical hysterectomy in a triplet pregnancy complicated by clear cell carcinoma of the cervix: a case presentation and literature reviewInt J Gynecol Cancer20122271198120222801030

 PubMed Web of Science ®Google Scholar

FruscioRVillaAChiariSDelivery delay with neoadjuvant chemotherapy for cervical cancer patients during pregnancy: a series of nine cases and literature reviewGynecol Oncol2012126219219722555106

 PubMed Web of Science ®Google Scholar

IslamSMukhopadhyayLHowellsRNeo-adjuvant chemotherapy and radical surgery for stage 1B cervical cancer in pregnancyJ Obstet Gynaecol201232219119222296440

 PubMedGoogle Scholar

ChvatalROppeltPKoehlerCHabelsbergerAYamanCSimple trachelectomy of early invasive cervix carcinoma in the second trimesterJ Turk Ger Gynecol Assoc201112212112324591974

 PubMedGoogle Scholar

LanowskaMKöhlerCOppeltPAddressing concerns about cisplatin application during pregnancyJ Perinat Med201139327928521391877

 PubMed Web of Science ®Google Scholar

LiJWangLJZhangBZPengYPLinZQNeoadjuvant chemotherapy with paclitaxel plus platinum for invasive cervical cancer in pregnancy: two case report and literature reviewArch Gynecol Obstet2011284377978321691768

 PubMed Web of Science ®Google Scholar

da FonsecaAJDalla-BenettaACFerreiraLPMartinsCRLinsCDNeoadjuvant chemotherapy followed by radical surgery in pregnant patient with invasive cervical cancer: case report and literature reviewRev Bras Ginecol Obstet2011331434821625793

 PubMedGoogle Scholar

GambinoAGorioACarraraLCancer in pregnancy: maternal and fetal implications on decision-makingEur J Gynaecol Oncol2011321404521446323

 PubMed Web of Science ®Google Scholar

CardonickEUsmaniAGhaffarSPerinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registryAm J Clin Oncol201033322122819745695

 PubMed Web of Science ®Google Scholar

FaveroGChianteraVOleszczukAInvasive cervical cancer during pregnancy: laparoscopic nodal evaluation before oncologic treatment delayGynecol Oncol2010118212312720460189

 PubMed Web of Science ®Google Scholar

ChunKCKimDYKimJHKimYMKimYTNamJHNeoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reportsJpn J Clin Oncol201040769469820427545

 PubMed Web of Science ®Google Scholar

RabaiottiESigismondiCMontoliSMangiliGCandianiMViganòRManagement of locally advanced cervical cancer in pregnancy: a case reportTumori201096462362620968145

 PubMed Web of Science ®Google Scholar

BoydACowieVGourleyCThe use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literatureInt J Gynecol Cancer200919227327619396008

 PubMed Web of Science ®Google Scholar

AbellarRGPepperellJRGrecoDEffects of chemotherapy during pregnancy on the placentaPediatr Dev Pathol2009121354118462010

 PubMed Web of Science ®Google Scholar

SeamonLGDowneyGOHarrisonCRDossBCarlsonJWNeo-adjuvant chemotherapy followed by post-partum chemoradiotherapy and chemoconsolidation for stage IIIB glassy cell cervical carcinoma during pregnancyGynecol Oncol2009114354054119523669

 PubMed Web of Science ®Google Scholar

BenhaimYPautierPBensaidCLhomméCHaie-MederCMoricePNeoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progressionEur J Obstet Gynecol Reprod Biol2008136226726817157432

 PubMed Web of Science ®Google Scholar

BaderAAPetruEWinterRLong-term follow-up after neoadjuvant chemotherapy for high-risk cervical cancer during pregnancyGynecol Oncol2007105126927217289127

 PubMed Web of Science ®Google Scholar

KaramAFeldmanNHolschneiderCHNeoadjuvant cisplatin and radical cesarean hysterectomy for cervical cancer in pregnancyNat Clin Pract Oncol20074637538017534393

 PubMedGoogle Scholar

PalaiaIPerniceMGrazianoMBellatiFPaniciPBNeoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case reportAm J Obstet Gynecol20071974e5e6

 PubMed Web of Science ®Google Scholar

CaluwaertsSvan CalsterenKMertensLNeoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literatureInt J Gynecol Cancer200616290590816681782

 PubMed Web of Science ®Google Scholar

MaranaHRde AndradeJMda Silva MathesACDuarteGda CunhaSPBighettiSChemotherapy in the treatment of locally advanced cervical cancer and pregnancyGynecol Oncol200180227227411161872

 PubMed Web of Science ®Google Scholar

TewariKCappucciniFGambinoAKohlerMFPecorelliSDisaiaPJNeoadjuvant chemotherapy in the treatment of locally advanced cervical carcinoma in pregnancy: a report of two cases and review of issues specific to the management of cervical carcinoma in pregnancy including planned delay of therapyCancer1998828152915349554531

 PubMed Web of Science ®Google Scholar

LaiCHHsuehSChangTCPrognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomyGynecol Oncol19976434564629062150

 PubMed Web of Science ®Google Scholar

GiacalonePLLaffargueFBen osPRousseauOHedonBCis-platinum neoadjuvant chemotherapy in a pregnant woman with invasive carcinoma of the uterine cervixBr JObstet Gynaecol199610399329348813319

 PubMedGoogle Scholar

JacobsAJMarchevskyAGordonREDeppeGCohenCJOat cell carcinoma of the uterine cervix in a pregnant woman treated with cis-diamminedichloroplatinumGynecol Oncol1980934054106247253

 PubMed Web of Science ®Google Scholar